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ABSTRACT
Cytochrome P450 enzymes are a large family of membrane heme proteins involved in
eliminating drugs and the synthesis or elimination of steroids, eicosanoids, and vitamins.
CYP2U1 is one of the poorly characterized P450 enzymes classified as orphan cytochrome P450
with unknown exact biological function. It is expressed in the brain and thymus as a catalyst in
the hydroxylation of arachidonic acid. Unlike other cytochrome P450s, CYP2U1 is a bit unusual
with forty extra amino acids. If a mutation occurs, it can lead to an early onset inherited disorder
of the central nervous system called Hereditary Spastic Paraplegias (HSP). Most of the P450
enzymes in humans are known and characterized based on their structure and functions. Many
of them have orthologous proteins in other species. CYP1A2 metabolizes many substrates like
phenacetin, caffeine, acetaminophen, and theobromine (from chocolate) which makes it likely
that there are differences between the activity of the canine and human CYP1A2 enzyme. The
human CYP1A2 protein is well characterized and has a crystal structure available. This has
implications in the treatment of canines in veterinary medicine and in drug metabolism studies,
which are sometimes conducted in dogs. Few studies have been conducted to look at the
biochemistry of the purified canine CYP1A2. Synthesis of the canine CYP1A2 gene and human
CYP 2U1 followed by cloning into the pCW plasmid was done and grown in E. coli JM109
cells for the production of large amounts of proteins that were isolated by breaking the cells
open through sonication, solubilized with the detergent CHAPS, and purified with Nickel
affinity and ion-exchange chromatography. The purity of the protein after purification was
measured by gel electrophoresis and UV-vis chromatography. The purified CYP 1A2 protein
was used to characterize the metabolism of caffeine, a substance known to be metabolized by
human CYP1A2.

KEYWORDS: cytochrome p450 enzymes, cyp 1a2, cyp 2u1, arachidonic acid, mutation,
hereditary spastic paraplegias
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CHAPTER 1: INTRODUCTION

1.1 Cytochrome P450 Family
Cytochrome P450 enzymes (CYP) are a large family of membrane heme proteins
involved in eliminating drugs and anabolism and catabolism of steroids, fatty acids, eicosanoids,
and vitamins.1-3 There are 57 human cytochrome P450s, and surprisingly almost a quarter of
them are categorized as orphan cytochrome P450s because their function, expression, and
regulation are not well understood. These heme-containing proteins catalyze a large variety of
oxidative reactions during metabolism involving a wide variety of endogenous and xenobiotic
substrates. 4 Cytochrome P450s are named so because of their unique nature to absorb light at
450nm when reduced and complexed with carbon monoxide due to the presence of a heme-iron
center that is embedded in their structure through a cysteine thiolate ligand. There are more than
50 CYP450 enzymes, but only a few are capable of metabolizing drugs expressed in the liver,
small intestines, kidney, lungs, and placenta. 5 They were first discovered in 1955 in rat
endoplasmic reticulum in the liver with oxidizing properties of xenobiotic substances. 6
1.1.1 Binding Partners. The required electrons for oxidative reactions are supplied
from the human cytochrome p450 reductase (CPOR), which has a molecular weight of 77kDa
and is composed of 55 amino acid N-terminal transmembrane domains, which transfers
electrons from Nicotinamide adenine dinucleotide phosphate (NADPH) through its cofactors
Flavin adenine dinucleotide (FAD) and Flavin mononucleotide (FMN) to the heme of the P450
(Figure 1). During the redox cycle, CPOR undergoes conformational changes between the
closed and open forms, but only the open state can transfer the electrons to the P450s.7
1

Figure 1. Cytochrome P450 in complex with the Reductase enzyme reproduced by Dr. Devore
1.1.2 The Catalytic Cycle. Figure 2 explains the catalytic cycle of P450s which are
initiated when the substrate binds to the active site leading to the displacement of the water
molecule normally attached to the heme (1). The binding of the substrate to the Cytochrome
P450 enzyme triggers a couple of events, such as the change of spin state of the prosthetic heme
and a change in the reduction potential, which is a complex process (2).
The substrates involved in binding are mainly hydrophobic and poorly soluble in water.
This leads to a change of state of the heme iron from the low spin to the high spin state7. The
high spin Fe3+ is quickly reduced to a ferrous state due to its high positive reduction potential
since water is a weaker ligand for the Fe2+ and the difference in states tends to increase the
stabilization of the ferric state in the absence of substrates. 8 Several factors play a role in the
resulting reduction potential. For instance, the higher the binding affinity of the substrate to the
active site of the P450, the stronger the water displacement effect resulting in a shift of the
reduction potential. 9
2

The presence of oxygen and carbon monoxide tends to have the same effect by binding
to the ferric iron of the enzyme. Changes in temperature and pH affect the resulting equilibrium
of the high-low spin of the P450s. The Oxy-P450 complex (3) formation through the binding
of oxygen molecules which is in turn reduced to a peroxo-ferric intermediate (4) and later
protonated to a hydroperoxo-ferric intermediate (5).
The effect of substrate binding reduces NADPH via cytochrome P450 reductase mostly
or other associated reductases through electron transfer.10 The second electron is transferred
from either cytochrome P450 reductase, ferredoxins, or cytochrome b5 after the binding of
molecular oxygen on the center of the heme at the distal axial coordination position to a peroxoferric intermediate. The distal oxygen atom is then protonated for the second time, yielding the
first highly reactive compound, an iron (iv) Oxo species, and water through heterolysis of O-O
bond (6) and subsequently oxygenation of the substrate to form a product complex.

1.2 Cytochrome 1A2
Cytochrome P450 1A2 is mainly located in the endoplasmic reticulum and is involved as
a catalyst to many reactions in the metabolism of drugs and synthesis of steroids and lipids. The
gene consists of seven exons and six introns. Human CYP1A2 consists of a 29 amino acid long
transmembrane domain, a heme in its catalytic domain of multiple residues on helix F and I, and
has a molecular weight of 58 kDa.11, 12. The core of the protein forms the heme-binding site and
the proximal surface, which is the binding sites for the redox partners; NADPH cytochrome
p450 oxidoreductase and cytochrome b5 is the most conserved region compared to other known
structure of the mammalian P450s.13

3

Figure 2. The Catalytic Cycle of cytochrome p450s. Used under public domain copyright.14

The structure is composed of 12 α-helices designated A-L and four β-sheets (1-4)
respectively, with several other helices present in other P450s designated with prime or double
prime designations as shown in Figure 3. Unlike the soluble prokaryotic P450s, the structure of
the mammalian P450 has hydrophobic surfaces on the tip of the protein and a large insertion
between helices. 15 P450s have different structural diversity and specificity that allows the
binding of substrates of different sizes.. 16 It has several different substrates like caffeine,
phenacetin, paracetamol, theobromine, and many others, which are mostly planar polyaromatic
amides and amines. 17
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Figure 3. Human Cytochrome 1A2 Crystal Structure, adapted from reference 18
Toxicosis of Caffeine in Canines: Homologs of cytochrome P450s in different species
often have similarities in the substrates that they metabolize. A lot of information is known about
the human CYP1A2 enzyme, but less is known about these enzymes in cats and dogs. 19 Caffeine
[(1,3,7)-trimethyl xanthine] is a natural plant alkaloid found in many plant species, beverages,
foods, and some medications and is generally considered a safe compound for consumption in
humans with a few mild effects.
It is one of the most consumed beverages believed to reduce fatigue as well as
enhancing mental alertness and concentration. However, this case is not the same with canines
since accidental consumption of caffeine has been reported to cause severe effects and even
death 20. Chocolate, xylitol, and grapes are some of the top ten poisons that were reported to the
Pet Poisons Helpline. Toxicity in canines has implications, on the drug metabolism studies that
5

are sometimes conducted in dogs as well as veterinary medicine. CYP1A2 metabolizes
substrates such as caffeine, phenacetine, and theobromine in coffee, etc., clearly indicating that
there are differences between the activity of canine and human CYP1A2.

1.3 Cytochrome 2U1
CYP2U1 is one of the orphan P450s mainly located in the brain and thymus, although
also distributed in other tissues such as the kidney, bladder, uterus, testis, and prostate.21 The
CYP 2 family is mainly composed of nine exons but, cytochrome 2U1 is highly distinct and
conserved with only five exons in its sequence with an unusually long N-terminal region with
eight proline residues and five arginine residues on its 20 amino acid insert along the
transmembrane helix (Figure 4). 22 The human CYP2U1 shares 99, 89, 88, 87, and 83 % amino
acid sequence identity with a chimpanzee, rat, dog, horse, and mouse, respectively, 23 and
contains almost 50 extra amino acids located at the N-terminus of the protein. 24 Different CYPs
can have the same substrates but generate different products. Drugs such as Debrisoquine and
terfenadine, antihistamines, 25 serotonin, fatty acids, and N- arachidonic acid are some of the
known substrates for CYP2U1. 23 Debrisoquine (Deb), a substrate to CYP 2D6 as well, has a
main metabolite 4-hydroxy-Deb with CYP2D6, but with a completely different metabolite when
metabolized by CYP2U1. CYP2U1 catalyzes the oxidation of Deb mainly to 1-hydroxy-Deb
with smaller amounts of 4-hydroxy-Deb, 6-hydroxy-Deb, and 8-hydroxy-Deb.26
The sequence alignment of the 57 human CYPs showed that CYP2U1 is the longest,
with at least 40 amino acids more than CYPs of families 2 and 3, and 13-33 amino acids more
than the CYPs of family 4. (Figure 5).23
6

Figure 4. Amino acid alignment of the members of the human CYP2 family adapted from
reference 22
Terfenadine (Terf), a derivative of terfenadine, was also analyzed with different CYPs.
26, 27

Terf and alkyl-Terf, Terf derivatives with replaced tertbutyl substituents with different alkyl

chains formed different products with CYP2J2, CYP3A4, and CYP2U1 with hydroxylation in
the homobenzylic position, N-dealkylation and hydroxylation in the benzylic positions,
respectively. (Figure 6) 28
CYP 2U1 plays a major role in the hydroxylation of arachidonic acid into two bioactive
metabolites, 19- and 20-hydro eicosatetraenoic acid and structurally long fatty acids like
docosahexaenoic acid. 21, 24 It is also suspected to play a role in iron transport and blood flow
control in some tissues or organs, as well as signal transduction modulator within immune cells
because of its hydroxylation properties of arachidonic acids, docosahexaenoic acids, and
eicosapentaenoic acids in the thymus. 24 Studies were done on the nonalcoholic smokers, and
nonsmokers as well as the alcoholic smokers and nonsmokers investigated expression levels of

7

Figure 5. N-terminal alignment of CYP 2 family, adapted from reference 22

Figure 6. Oxidation sites of Debrisoquine, terfenadine, and terfenadine derivatives by P450s
adapted from reference 22
CYP 2 proteins in the prefrontal cortex and amygdala and showed that CYP2U1 and CYP2E1
were expressed in all the samples and increased on alcohols and smokers. 29 These findings
might have implications on the metabolism of drugs and endogenous substances.30
8

Hereditary Spastic paraplegia (HSP): Rare CYP2U1 mutations have been associated
with several pathological situations and related to hereditary spastic paraplegia, a neurological
disorder of the Central Nervous System that is mainly characterized by gradual spasticity and
weakness of the lower limbs. 31-35 These symptoms either occur alone or with other neurological
signs. Genetic studies in HSP have shown the alteration of the molecular and cellular pathway
caused by changes in fatty acid, sphingolipid, and phospholipid metabolism.35 SPG56 is a rare
form of HSP due to mutations in CYP2U1. Less than 15 families have been reported so far with
truncating, and missense variants in CYP2U1 observed with either homozygous or heterozygous
states. 34 A study was done on the SPG56 patients, and it was observed that most of the missense
variants led to inhibition of enzymatic activity due to the loss of the proper binding of the heme
to the protein or modification of the protein structure. 33

1.4 Project Objectives
The project goal is to clone the purchased gene for CYP2U1 into the pCW plasmid and
use PCR for amplification. For canine CYP1A2, though, the gene was purchased pre-cloned into
pCW by Twist Bioscience. The cloned gene is expressed in E. coli culture, sonicated to lyse the
cells, solubilized with cymal-5 detergent, and separated solubilized protein by centrifugation.
Purification of the protein is conducted using affinity chromatography followed by ion-exchange
chromatography. The purpose of this project is to perform metabolic assays using HPLC to
analyze and quantify canine CYP1A2 metabolism of caffeine in comparison to humans after
purification. Protein crystals will be screened using purchased crystal kits. High-quality crystals
are required to determine the crystal structure of both proteins through X-ray diffraction
experiments, so crystals will likely need to be optimized before X-ray diffraction experiments.
9

CHAPTER 2: MOLECULAR BIOLOGY

The manufacture of well-defined and specific proteins and antibodies has been improved
immensely by recombinant DNA technology with a complete solution in cloning and expression
of the gene of interest. With this technology in hand, there is a possibility of designing and
tailoring artificially an enzyme that can perfectly meet the requirements such as altered substrate
specificity, kinetic activity, or enhanced thermal stability.
This technology depends on the ability of the restriction enzymes to cut the DNA of interest
and that of the ligase in rejoining the DNA molecule in vitro into a vector to be transformed into
host cell that is convenient to be manipulated experimentally through extraction and
purification. Restriction endonucleases are essential in recombinant technology because they
recognize a short, specific sequence of nucleotide bases that are randomly distributed throughout
the DNA and cut it by catalyzing the hydrolysis of the adjacent nucleotide bonds. This ability to
cut DNA at specific locations by these enzymes has led to many advancements involving the
isolation of gene by researchers and their combination with other DNA molecules. 36 This
chapter focuses on the theory and introduces the background of molecular cloning of
cytochrome 2U1.
Polymerase Chain Reaction (PCR)-The principle of PCR requires three-step cycling;
denaturation of the double DNA strand, annealing of the primers, and the extension of the
primers (Figure 7). The components that are essential in this process include: (i) the DNA
template to be copied, (ii) the primers, (iii) DNA nucleotide bases needed for DNA synthesis,
(iv) DNA polymerase enzyme, and (v) a buffer to provide a suitable environment for the
reaction. Denaturation of the double-stranded DNA duplex that is held together by hydrogen
10

bonds is mainly achieved through heating at 95-100˚ C. The primers, which are single-stranded
nucleotide sequences complementary to one of the original DNA strands, are then attached to
the dissociated ssDNA strands in the annealing process. The primers are most often in excess for
the annealing to take place more effectively than the reannealing of the dissociated strands. The
last step involves the use of an enzyme DNA polymerase which adds nucleotides
complementary to the unpaired DNA strand on the annealed primers.
A cycle takes 3-5 minutes repeated 20-40 times. This process requires a heat-liable
polymerase enzyme to increase the yield, improve sensitivity and the length of the target DNA
to be amplified. 36

Figure 7. Theoretical amplification of PCR products. This image was made by Enzoklop, CC
BY-SA 4.0 <https://creativecommons.org/licenses/by-sa/4.0>, via Wikimedia Commons
Electrophoresis is a highly sensitive tool that is used to study, identify, and characterize
proteins. 36 Biomolecules such as DNA, RNA, and proteins can be separated by the
electrophoresis technique through migration on a matrix upon application of an electric current
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(Figure 8).36 Agarose, which is used to separate larger biomolecules such as nucleic acids and
polyacrylamide gels for proteins, are the most used and available support matrices.36 Sodium
dodecyl sulfate (SDS) polyacrylamide gel electrophoresis is one of the common forms of
electrophoresis used to separate proteins based on size requires denaturing the activity of the
protein, hence could not be used for further analysis that requires the retention of the biological
activity of the protein of interest. 36 The effectiveness of the polyacrylamide gel is determined by
the pore size, choice of the buffer to be used, pH, amongst other factors. 36
The electrophoresis instrument is composed of the power supply source and a chamber
for holding the running buffer and the samples. 36 A running buffer at a higher pH causes the
biomolecules to be negatively charged, migrating from the cathode to the anode and vice versa
at lower pH. 36 The use of dyes, fluorescent tags, or radioactive labels enables the DNA on the
gel to be seen after they have separated and appears as bands on the gel. 36 A DNA marker with
fragments of known lengths is run through the gel at the same time as the samples to determine
the approximate number of base pairs in the sample. 36

2.1 Methodology
Polymerase Chain Reaction. Two PCR tubes are prepared with the following contents:
35.5µL of autoclaved water, 1µL CYP 2U1, 1µL dNTPs (deoxynucleotide triphosphates), 1µL
forward primer, 1µL reverse primer, 10µL 5x GC buffer, and 0.5µL Phusion polymerase. The
PCR tubes are then placed on the PCR machine and run. Method of PCR2 setup is provided in
Table 1. Restriction digestion was then conducted by the addition of 1µL Hind III, 1µL NdeI,
and 5µL FD buffer to the PCR product.
12

The tubes are thereafter placed in the incubator for 1hour. DNA cleaning and
concentration were done using Zymo’s DNA Clean & Concentrator -5 kit. First, the PCR
products were placed in a 1.5 Eppendorf tube, and 500µL of the binding buffer was added. The
contents are centrifuged at 10,000rpm for thirty seconds, and the eluent is poured into a beaker.
200µL of the wash buffer is then added and centrifuged at the same speed for thirty seconds and
the eluate discarded. This procedure is done twice, and 10µL of the DNA elution buffer was
added and incubated for one minute at room temperature. Centrifugation is done, and the eluate
that is with the concentrated DNA is stored.

Figure 8. Electrophoresis principle. The negatively charged biomolecules move towards the
cathode with applied electric current. Image by Jjw, CC BY-SA 3.0, via Wikimedia Commons,
this image was not modified.

DNA Gel Electrophoresis was done to determine whether the PCR amplification
procedure was successful or not. A gel is prepared by weighing out 1.5g of agarose that is put in
the beaker and 100ml of 1x TAE buffer added. The contents are heated in the microwave for
30minutes carefully to dissolve the mixture. Once it was dissolved, the contents are poured on
the gel runner, and the well comb was placed on one end and allowed to cool on the counter.
The comb is taken out after gelling is complete, and the runner is placed on the electrophoresis
13

chamber. The 1X TAE buffer is added, and 10µL of the DNA ladder and 5µL of the PCR
product with EZ vision one microliter of visualization dye carefully added onto the wells. The
Bio-Rad Powerpack™ Basic is turned on and the voltage set at 180 V, and the gel was run.

Table 1. PCR2 method for Veriti 96 Well Thermo Cycler.
Stage
Step
Temperature° C

Time (s)

1

1

98

30

2

1

98

10

2

53

30

3

72

60

1

72

120

2

4

Indefinitely

3

Cell transformation. 50 µL of JM 109 cells were put on ice for thirty minutes, added 2µL
of pCW 2U1. The cells were heat-shocked in a hot water bath for thirty seconds and placed back
on ice for two minutes. The mixture is pipetted onto the prepared LB-Amp plate, and glass
beads are added and swirled around for a thin layer of cell formation. The plate is placed on the
incubator at 37℃ overnight for colony production.

2.2 Results and Discussion
PCR was successful, as indicated by the PCR product (Figure 9). The first lane is the
DNA ladder, and lanes 4-7 are the PCR products visualized with a fluorescent dye under a UV
light source. The bands obtained from the PCR products were dissected, and the DNA extracted
14

from the gel using the Zymoclean Gel DNA Recovery Kit. The visualized PCR product and an
empty plasmid backbone needed to be ligated together to make the pCW 2U1 vector with 2.5µL
ligase in a 3:1 ratio. Transformation is then done after incubation and plated onto the lysogeny
broth ampicillin (LB-amp) plate. The plate was incubated overnight and there were no colonies
observed the next morning. Numerous attempts were made in the ligation and transformation
steps with no success and a third party was contacted for cloning purposes. A full plasmid was
obtained with the CYP2U1 gene, transformation done and several colonies obtained for
expression and purification.

1

2

3

4

5

6

7

Figure 9. DNA agarose gel of CYP2U1 PCR sample. Lanes 4-7 contain PCR products. Lane 1
contains a DNA ladder.

2.3 Conclusion
Cloning was not successful in the CYP 2U1 project, and a company was contacted to
produce a full vector for both the CYP 2U1 and CYP 1A2 projects. The pCW vector was
suspected to be the cause of the problem as there were similar issues with one or two projects
15

involving the subcloning step with CYP project. The next step was the expression and
purification after successful sub-cloning.
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CHAPTER 3: EXPRESSION AND PURIFICATION

Protein insolubility, conformation, stability, structural stability, host cell toxicity as well
as low purification yields are some of the factors that must be addressed for efficient expression
and purification processes. All the cytochrome P450s investigated in this thesis utilized an E.
coli expression system to grow large amounts of protein. After expression in E. coli, cells are
lysed to isolate the desired protein product. The use of affinity tags has been used to address the
challenges of isolating the desired protein and for the modification of protein of interest for
efficient protein identification, production, and isolation from the host cells. This technique
utilizes a short sequence of amino acids that are added to the proteins of interest on either the Nterminus or the C-terminus.
Polyhistidine tags are one of the commercially available affinity tags that are used
mainly for the purification of poly His-tagged proteins using the immobilized metal affinity
chromatography based on the interaction between the negatively charged Histidine residues and
transition metals that are immobilized on the matrix, such as Nickel or Cobalt, with the unbound
proteins removed during the washing step followed by the elution of the pure protein.[34] Ni (II)nitrilotriacetic acid (Ni-NTA) has many advantages such as high affinity for histidine residues
and capabilities to withstand multiple regeneration cycles and allows dissociation of the bound
proteins with the use of low concentrated imidazole or changes in pH.37 The use of imidazole,
however, may result in protein aggregation or inactivity after purification, and it is highly
recommended to perform dialysis for further assays, especially those involving crystallography
and NMR experiments. 38-40

17

3.1 Protein Expression
A resistance marker is added to the plasmid backbone to prevent the growth of plasmid
free cells in the culture using an antibiotic resistance gene that is present in the bacterial host
system. E.coli is the most widely used host system for the expression of proteins because of (i)
fast growth rate, (ii) cells can be grown to high density for protein production, iii) low costs, and
simple culturing conditions. 41
3.1.1 IPTG Induction. IPTG is used to turn on the production of the desired protein since
its concentration does not reduce rapidly as compared to lactose. It is similarly imported into the
cell as a lactose metabolite stimulating the expression of proteins in the lac operon with a constant
rate of protein expression. Presence of IPTG in the medium, inhibits Lac I from binding to the Lac
O and as a result gene transcription is initiated leading to the growth of the protein of interest. 42
3.1.2 Detergent Use for Membrane Protein Isolation. Detergents are used for the
extraction of membrane-bound proteins by mimicking the physical and chemical properties of
the lipid membrane and increase their solubility, which is an important factor in protein
purification 39 This has impacts on the retention of the protein activity, and a special buffering
system has to be improvised. Purification of these proteins uses the same chromatographic
techniques as the other soluble proteins, but the main difference is always the use of the
detergents in the buffers. The use of detergents, however, can affect the stability of the protein,
which could interfere with binding assays and biochemical processes. 43
Detergents are amphipathic with polar or charged head groups and an extended
hydrophobic hydrocarbon chain and tend to aggregate into micelles at high concentrations
interacting with both the solvent and the nonpolar surfaces of the protein. 44
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3.2 Affinity Chromatography
This is a type of liquid chromatographic technique with high-specificity interactions for
separation and analysis purposes. The support matrix is usually composed of porous materials
such as agarose, polyacrylamide, cellulose, and silica. A suitable ligand must be identified and
placed onto the solid support of the column to interact with the biomolecule of interest
selectively. The sample of interest is first injected into the column under conditions that the
analyte will strongly bind to the immobilized ligand. Most of the other solutes in the sample are
quickly washed from the column because they are incapable of binding to the ligand (Figure 10).
An elution buffer is thereafter injected to dissociate the retained solutes in several ways, such as
changing the pH or buffer composition of the mobile phase to either decrease the strength of the
ligand-analyte interaction or by introducing a competing agent to displace the analyte from the
ligand. The analyte is detected as it elutes and collected for later use as the column is regenerated
for later use. This separation technique is highly selective and easy to perform for solute
purification and quantification. 45, 46

3.3 Ion-exchange Chromatography
Biomolecules such as proteins have exposed charged moieties at the surface that could
interact with ion exchangers depending on the pI of the protein and the pH of the environment.
The principle is based on the interaction between oppositely charged molecules. The ion
exchanger is composed of a matrix immobilized with positively or negatively charged ligands.
There are two types of ion-exchangers: cationic exchangers with carboxymethyl functional
groups that are negatively charged or anionic exchangers with diethyl aminoethyl functional
groups that are positively charged. A protein is negatively charged when its charge is above its pI
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and could easily bind to an anionic exchanger and vice versa. Desorption of the analyte
molecules is easily done by increasing the salt concentration or changing the pH of the buffer. 36
However, increased salt concentration tends to increase the surface tension of the water causing
competition between the protein and the salt ions for hydration. This may in turn denature the
protein by stripping off the essential layers of the water molecules from the protein
surface.37

Figure 10. Principle of affinity chromatography. Image was adapted from
https://www.biorad.com/webroot/web/images/lsr/solutions/technologies/lab_scale_chromatogra
phy/chromatogra phy/technology_detail/chromt11
3.4 SDS Page
A gel matrix is used in electrophoresis for the separation of proteins based on size,
charge, and structure. SDS-page separates proteins based on their sizes, and this is because of the
incorporated SDS detergent that denatures and binds to protein causing them to be negatively
charged. These SDS-bound proteins migrate towards a positively charged electrode when current
20

is applied through the gel matrix. Smaller proteins migrate faster due to less resistance on the gel
matrix as compared to larger ones. Once separated by electrophoresis, they can be detected using
stains and their sizes determined by the protein ladder available commercially.

3.5 Methodology
Media preparation. LB media preparation: 2 grams of Tryptone, 1 gram of yeast extract,
and 2 grams of Sodium Chloride were added in a 500ml Erlenmeyer flask, and deionized water
added to 200 ml volume. The top was sealed with aluminum foil and autoclave tape and ran on
the autoclave on a liquid cycle. The contents were allowed to cool once the cycle was completed
and stored. TB media preparation: Three flasks was prepared for the expression of CYP 1A2 and
six flasks for CYP 2U1. In each 2 L flask, 50.4 grams of prepared Terrific Broth powder was
weighed, 4ml of 100% glycerol added, and the volume brought to 1000ml with deionized water.
The top is sealed with aluminum foil and autoclave tape. The solution is then placed on the
autoclave and run on a liquid cycle. The solution is then stored under cool temperatures after
cooling for later use.
3.5.1 Buffer Preparation. All the purification buffers were prepared from 1M
potassium phosphate stock at pH 7.4 prepared by measuring 800mL of deionized water into a
beaker. 163g of K2HPO4 and 8.88g of KH2PO4 were added to the beaker. The pH is adjusted to
7.4 using a pH meter with sodium hydroxide and 1M hydrochloric acid solutions and the volume
adjusted to 1L with deionized water. The ratios of different reagents used to prepare buffers are
shown in Table 2.
3.5.2 Cell Transformation. 1 µL of the pCW 1A2 or 2U1 containing plasmid was mixed
with 50µL of JM109 competent cells and placed on ice for thirty minutes.
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Table 2. Reagents for purification buffers
1M potassium
Buffer name
phosphate buffer(mM)

Glycerol

NaCl

Imidazole

(%v/v)

(mM)

(mM)

Resuspension
buffer

500

10

300

0

Ni-NTA wash

100

10

300

10

Ni-NTA elution
buffer

100

10

0

200

Ion-exchange
wash buffer

50

10

0

0

Ion-exchange
elution buffer

100

10

500

0

buffer

The cells were heat shocked in a 37˚ C hot water bath for thirty seconds after the
incubation period and placed back on the ice for two minutes. The mixture is pipetted onto the
prepared LB-Amp plate, glass beads added and swirled around for a thin layer of cell formation.
The plate is placed on the incubator at 37℃ overnight for colony production
3.5.3 Expression of CYP 1A2 and CYP 2U1. A single colony of transformed cells was
picked and added to the 200 ml LB media, and ampicillin was added. This starter culture is
grown overnight at 37℃ on the incubator at 180 rpm. The contents are then distributed into the
22

three flasks of TB media the following morning, and ampicillin solution added. The cells were
grown shaking for three hours, and the OD600 was measured. Β-D-1-thiogalactopyranoside
(IPTG) and aminolaevulinic acid (ALA) were added to each flask, and the temperature was
reduced to 32℃, and the cells were allowed to grow for three days.
The cells are then harvested by centrifugation. The cells are equally distributed on four 400ml
centrifuge tubes and centrifuged at 5000rpm for 20 minutes, and the supernatant discarded. The
procedure is repeated until all the growth media has been centrifuged and the pellet resuspended
with a resuspension buffer, and either stored or protein extraction done.
3.5.4 Protein Extraction. The pellets that were resuspended with the buffer are placed
on a beaker and placed on ice. The tip of the sonicator probe is put near the bottom of the beaker
for thirty seconds followed by a rest for another thirty seconds, alternatingly for at least three
minutes. The probe is removed and a stirring rod placed into the beaker. The beaker is then
placed into a dish with ice on a magnetic stirrer. While stirring, 3.2 mM Cymal-5 detergent
added during the extraction step in addition to 1%v/v CHAPS with CYP1A2, but not included in
the buffers which only contained 0.5%v/v. Same concentration of CHAPs detergent is used with
CYP 2U1 with the exemption of Cymal- 5 detergent. The mixture is stirred for one hour on ice
and then put into the centrifuge tubes. Centrifugation is done at 20000 rpm for 20 minutes, and
the supernatant is stored for purification at -80 °C.
3.5.5 Protein Purification. A column with NiNTA beads is connected to the Bio-Rad
Biologic LP Chromatography instrument and flushed with resuspension buffer. The lines A, C,
D, and E are used and connected to the lysate, resuspension buffer, wash buffer, and elution
buffer, respectively. Once everything is well set, purification is started, and the fractions are
inspected and collected with the protein of interest.
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The fraction with the protein of interest is placed on line C on the ion-exchange chromatography
for further purification, while the ion exchange wash buffer and elution buffer are placed on
lines D and E, respectively. The fractions with the purified protein are collected afterwards.
3.5.6 Absolute and Carbon Monoxide Spectra. 750µL of elution buffer with detergent
is placed on the cuvette and used to auto-zero and baseline the UV-VIS. Another cuvette is used
once this is done, and 750µL of the fraction is collected and scanned at a wavelength range of
750-250nm. The scan is saved, and a few crystals of sodium dithionite are added into the cuvette
with the purified sample and the UV-VIS instrument auto-zeroed and baselined once more. The
cuvette is bubbled with carbon monoxide and scanned at a range of 500-400nm to obtain a CO
difference spectrum.
3.5.7 SDS-PAGE Analysis. Different fractions are collected including the flow-through
with the lysate, the fraction with the wash buffer, as well as the elution buffer.10µL of the
fractions are pipetted into an Eppendorf tube and 10µLof the loading dye with βmercaptoethanol added to each solution. One Eppendorf with the protein ladder and the loading
dye is also created with the same volume measurements. The comb and the tape on the gel are
removed gently and the gel placed in the gel electrophoresis apparatus.
The SDS PAGE 10X electrophoresis buffer is prepared by dissolving 30.0g of Tris base, 144.0g
of glycine, and 10.0g of SDS in 1000ml of deionized water at a pH of 8.3 and stored at room
temperature. The running buffer is prepared from the 10X electrophoresis buffer by adding 50ml
of the electrophoresis buffer into 450ml deionized water.
The running buffer is added to the gel runner and the samples loaded into the wells. The
voltage is set to 210V, and the samples run carefully, observing the production of bubbles from
the bottom of the gel. Once complete, the gel is carefully placed in water for staining. Coomassie
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stain is added to the gel and placed in the microwave for 20 seconds. Water is added to the gel
and microwaved again for two minutes. This process is done alternatively until the bands are
easily seen.

3.6 Results and Discussion
Figure 11, briefly describes the processes conducted from the growth of the protein with
the starter culture at 32°C for 24 hours which is then scaled up with the Terrific Broth media and
allowed to grow further for 3 days for production of large amounts of the protein with addition of
IPTG and ALA, harvested, extracted by use of sound waves and detergents and the lysate
obtained after centrifugation at 5000rpm for 20minutes. The lysate is then purified by affinity
chromatography with the resuspension, wash and elution buffers. Purification of CYP 1A2 and
CYP 2U1 was repeated several times and optimized for better yields, such as the use of different
detergents like CHAPS, Cymal-5, and Anapoe-35. The protocol with better yields was adopted
for the purification of these proteins. Different conditions had to be optimized to improve the
overall yields for CYP 2U1.
Cymal-5 detergent was used initially for the extraction of the CYP 2U1 with little success
in binding to the cobalt column. The pH of the buffers used were not adjusted and was suspected
to be the cause but there were no much improvements afterwards after fixing this issue. The
concentration of IPTG and ALA were slightly increased during expression, switched the
detergent to Anapoe-35, with little or no success since the overall yield was lower than 0.15µM
as described in Table 1. Improved yields and binding were observed with the use of Nickel
column for affinity and DEAE beads for ion-exchange chromatography with CHAPs detergent.
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Nickel column was used for purification, as shown in Figure 12 followed by ion-exchange
chromatography.

Figure 11. (A) The LB media used as the starter culture with inoculation of a single colony, B)
TB media used for scale up for three days (C) Harvested protein by centrifugation (D) P450
protein to be purified after extraction.
3.6.1 Affinity Chromatography. The fractions collected with the elution buffer were
selected and pooled for further analysis. The detailed assignment of this protein was made based
on UV-VIS analysis. The ratio of heme to protein content, as monitored by the absorbance ratio
A 420/A280, indicated that the protein of interest was present but with low yields.
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Figure 12. Nickel affinity chromatography purification technique with lines A, C, D and E
representing the columns with the lysate, resuspension, wash and elution buffers respectively
with the Bio-Rad Biologic LP Chromatography instrument.
Figures 13, and 14 show the absolute spectra of CYP 1A2 and CYP 2U1 after Nickel affinity
purification with buffers at pH 7.4.
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Figure 13. CYP 1A2 affinity absolute spectrum. The absorbance ratio at 420nm and 280nm
wavelength used to determine the purity of the protein after affinity purification.

Figure 14. CYP 2U1 affinity absolute spectrum obtained to deduce the protein and heme content
before ion-exchange purification.

28

The purified protein was confirmed by the CO difference that indicated the presence of
the P450 heme with a concentration of 0.30µM for CYP 2U1 and 0.84µM for CYP1A2. The
remaining fraction was saved for ion-exchange chromatography in Figures 15 and 16.

Figure 15. A Carbon monoxide spectrum confirming the presence of CYP1A2. A base line done
after the addition of an excess sodium dithionite to the cuvette and the difference spectrum
obtained after bubbling carbon monoxide for 45s.
3.6.2 Ion –exchange chromatography. The ratio of heme to protein improved
drastically close to 1:1 after the second purification was conducted for both proteins as expected
measured by absorbance A280/ A420nm.
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Figure 16. CYP 2U1 CO difference spectrum indicating the presence of the CYP 2U1

Figures 17 and 18 are the absolute spectra obtained after purification with ion- exchange
using DEAE matrix.
3.6.3 Purification of Cytochrome b5. Cytochrome b5 was thawed and sonicated five
times. It was then centrifuged for 25minutes at 19000rpm. 20ml of the resuspension buffer is
then added and ground into solution. 1% of CHAPS detergent is added and stirred for one hour.
It is then loaded into the Nickel column after centrifugation at 19000rpm for 30minutes. The
yield produced was low, with a concentration of 2.06µM. This protein was saved at -80°C to be
used for caffeine metabolism assay.
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Figure 17. CYP 2U1 absolute Ion- exchange spectrum, improved

Figure 18. CYP 1A2 Absolute Ion-exchange spectrum with improved heme to protein ratio at
420nm and 280nm wavelength.
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The CO difference obtained afterwards are as shown in Figures 19 and 20.

Figure 19. CYP 1A2 DEAE CO difference spectrum

Figure 20. CYP 2U1 DEAE CO difference spectrum
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3.7 Conclusion
Purification of CYP 2U1 was not an easy task as several factors had to be varied on the
protocol, such as optimization of pH, detergent to be used, as well as the column to be selected
for affinity chromatography. The choice of the buffer and pH to be used plays a role in
purification process depending on the solubility of the protein and the potential effects on the
stability of the solution which may result in denaturation or precipitation thereby affecting its
purity. CHAPs detergent tremendously improved the extraction and subsequent binding of the
protein to the matrix of nickel column. This was observed with an increase in intensity of the
brown color of the lysate after centrifugation due to the presence of heme in P450s. Substantial
amounts of expression media were used to increase the yields as listed in the Appendix.
Particularly for CYP2U1, as it was discovered that a growth of 6 Liters of media was required
for sufficient yields of the protein. Purification was successful, and the proteins were stored for
further assays.

33

CHAPTER 4: X-RAY CRYSTALLOGRAPHY

Scientists can determine the structure of proteins using x-ray crystallography, a
technique that provides a three-dimensional structure from a crystal. A purified and concentrated
protein is required for the crystals to grow under the right conditions, and for this to occur, many
factors must be put into consideration on a trial-and-error basis. The choice of precipitant, its
concentration, the buffer to be used, pH, the concentration of the protein, and the temperature
are among the various variables that must be put into consideration for successful crystal
growth. 47, 48 Different crystal screens are available for the crystal setups with the precipitant,
buffer, salt, and pH varied that can be tried with the purified protein; however, none of these
conditions are guaranteed to grow crystals.49 These can be used with different techniques
(Figure 21), such as the hanging drop vapor diffusion where the drop is with an equal volume of
the concentrated protein and the reservoir solution suspended over the reservoir from the glass
coverslip, or the sitting drop diffusion technique with the drop placed on a special diffusion
chamber, or the dialysis technique.50, 51 The hanging drop diffusion occurs when the protein
crystallizes as the vapor pressure of the solution rises.

4.1 Methodology
The purified CYP 2U1 and CYP 1A2 that were collected from ion- exchange with the
elution buffer was concentrated for crystallography assay. The fractions were put into the
Amicon Ultra filter tube with 25k Da cut off and centrifuged. UV-VIS was then used to
determine the concentration of the protein by applying Beers Law using the coefficient factor,
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absorbance at 410 nm, and the path length of the cuvette. Centrifugation of the fractions was
done to achieve at least 200 µM concentration, and the sample was stored for crystallography.

Figure 21. Crystallization techniques. https://www.pathsense.eu/wp
content/uploads/2018/01/drops.png
Hampton Research crystal 1 and 2 were used for the 96-reagent setup of CYP 1A2, while
Memphac was used for CYP 2U1 protein by pipetting 75µL of each reagent into the crystal
screen tray. 0.5µl of the sample and the reagent were then pipetted into the sample well, and the
sample tray was covered and incubated at 19°C and stored to be checked after few days. A
crystal hit is optimized in a 24 well plate using the volume and concentrations that were varied
based on the initial hit conditions using the crystal plate builder on Hampton Research’s website
into the crystal tray while 0.5 µL of the sample and reagent are carefully pipetted into the
coverslip. The coverslips are then sealed with grease or immersion oil and incubated at 19°C and
checked after few days as well.
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4.2 Results and Discussion
The crystals that were initially observed with CYP 1A2 (Figure 22) with the crystal plate
that was incubated at 19°C with the well G3 (0.01 M Zinc Sulfate heptahydrate, 0.1M MES
monohydrate pH 6.5, 25%v/v Polyethene glycol monomethyl ether 5,000 and A1 (0.02 M
Calcium Chloride dihydrate, 0.1M Sodium acetate trihydrate pH 4.6, 30% v/v (+-) 2- Methyl -2,
4-pentanediol). These crystals did not grow further, and the remaining purified CYP 1A2 was
used for metabolism assays instead of further crystal screening.

Figure 22. CYP 1A2 crystals with G3 (0.01 M Zinc Sulfate heptahydrate, 0.1M MES
monohydrate pH 6.5, 25%v/v Polyethene glycol monomethyl ether 5,000 and A1 (0.02 M
Calcium Chloride dihydrate, 0.1M Sodium acetate trihydrate pH 4.6, 30% v/v (+-) 2- Methyl -2,
4-pentanediol).
The CYP 2U1 crystal hit (Figure 23) was in well H9 of the well plate out of 96 wells set
with conditions, (0.2M Zinc acetate dihydrate,0.1M Sodium cacodylate trihydrate pH 6.5, 18%
w/v Polyethene glycol 8,000) This was further optimized, and Figure 24 shows the crystals that
were observed afterward.
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Figure 23. CYP 2U1 crystal hit with condition H9 (0.2M Zinc acetate dihydrate,0.1M Sodium
cacodylate trihydrate pH 6.5, 18% w/v Polyethene glycol 8,000).

Optimization was done and incubated at 19°C with well plate A1 (0.1M Zinc acetate
dihydrate 0.1M Sodium cacodylate trihydrate pH 6.5 1% Polyethylene glycol 8,000, B3 (0.15M
Zinc acetate dihydrate 0.1M Sodium cacodylate trihydrate pH 6.5 13% Polyethene glycol 8,000)
and B2 (0.15M Zinc acetate dihydrate 0.1M Sodium cacodylate trihydrate pH 6.5 9%
Polyethylene glycol 8,000 as in Figure 24.
4.3 Conclusion
Initial crystal screen setups are based on a trial-and-error procedure with an aim of
covering a broader range of variables as possible using commercially available crystal screen
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packages. The purified protein has to be concentrated in order to increase the chances of a
crystal growth. At this stage, it is common to see various combinations ranging from nothing,
precipitation, or showers of microcrystals. Optimization has to be done with the crystal observed
after screening with varying conditions for crystal growth. The crystal hits that were obtained
disappeared after a few weeks; better crystals might have been observed with increased
concentration of the purified protein.

Figure 24. CYP 2U1 crystals after optimization with conditions A1(0.1M Zinc acetate dihydrate
0.1M Sodium cacodylate trihydrate pH 6.5 1% Polyethylene glycol 8,000), B3 (0.15M Zinc
acetate dihydrate 0.1M Sodium cacodylate trihydrate pH 6.5 13% Polyethene glycol 8,000) and
B2 (0.15M Zinc acetate dihydrate 0.1M Sodium cacodylate trihydrate pH 6.5 9% Polyethylene
glycol 8,000)
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CHAPTER 5: CAFFEINE METABOLISM

In humans, the metabolites of caffeine are paraxanthine (84%), theobromine (12%),
theophylline (4%), and 1, 3, 7-trimethyluretic acid (1%), which are further broken down and
excreted in the urine (Figure 25). Caffeine’s mode of action is through antagonistic effects to
adenosine and its receptors that cause drowsiness and fatigue. 52, 53 The dog enzyme is of
particular interest because although the enzyme is 80% identical to the human enzyme, dogs
metabolize caffeine and theobromine, known substrates of human CYP1A2, at much lower
rates. Chocolate and caffeine are some of the reported toxic foods in canines that are rapidly
absorbed from the gastrointestinal tract into the bloodstream after ingestion and metabolized in
the liver. 19

Figure 25. Caffeine metabolism.https://commons.wikimedia.org/wiki/File:
Caffeine_metabolites.svg">Icey</a>, Public domain, via Wikimedia Commons
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5.1 Methodology
CYP 1A2 (30 pmol), cytochrome b5 (60 pmol), and human reductase (180 pmol) were
pipetted and added into a 1.5 ml Eppendorf tube. The mixture was vortexed for 5 seconds and
placed in a hot water bath for 30 minutes at 37°C. Then, 6 µL of 10 mM Caffeine, 15 µL of
NADPH, and 154 µL of 1M potassium phosphate buffer were then added and incubated for 20
minutes. The reaction is further stopped by the addition of 15 µL of 6 M HCl acid. Samples
were centrifuged at 12,500 rpm to remove any precipitated protein and placed in an HPLC vial
for analysis.
Chromatographic conditions- HPLC analysis was performed by isocratic elution at a
flow rate of 0.8 ml/min. The mobile phase composition was 15% acetonitrile, 1% acetic acid and
84% water run at a flow rate of 0.8ml/min at 275nm detector wavelength. Column used was
Luna C18, 1500mm length and 46mm diameter. The injector volume used was 25µL.

5.2 Results and Discussion
The method used for HPLC analysis was developed from the Instrumental Analysis lab
used for the determination of Caffeine, Theophylline, Theobromine using HPLC. A solution of
10 mM caffeine, theophylline, and theobromine were run after filtration to an auto sampler vial
on HPLC for 12 minutes to indicate and determine the positions of the different compounds
(Figure26).
The human reductase that was used ran out, and purification attempts by Dr. DeVore had
poor yield and protein that was not active. A rat reductase was purchased instead, and we are
hopeful that this protein will allow us to continue these experiments.
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Figure 26. Caffeine, Theophylline, and Theobromine separated by HPLC analysis.
The first chromatogram (Figure 26) shows retention times for caffeine and its
metabolites while the second chromatogram (Figure 27) shows the CYP 1A2 assay with the
human reductase enzyme and shows the metabolite peaks at approximately 3minutes, 3.5
minutes, and 4.2 minutes showing the positions of theobromine (3.5 min), theophylline (4.2
min), and maybe paraxanthine (3.0 mins).

Figure 27. CYP 1A2 assay with human reductase, retention peaks at 3mins,3.5mins and 4.2 mins
shows the metabolites produced.
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5.3 Conclusion
Cytochrome P450s require an additional protein during oxidative reactions for the
provision of electrons. The human cytochrome reductase gene was purchased, transformed in E.
coli cells, expressed and purified using Nickel affinity for the transfer of electrons from NADPH
using its flavin moieties into the heme of CYP 1A2 for an efficient metabolism of caffeine. The
method used was suitable for the identification and can be used for the quantification of
caffeine, theophylline, theobromine and paraxanthine.
Figure 26 shows the retention peaks of Theobromine, Theophylline and Caffeine to be at
approximately 4.2mins, 5.8mins and 9.2mins respectively whereas the retention time observed
with the CYP 1A2 assay as in Figure 27 indicated the retention times for NADPH, paraxanthine,
theobromine, theophylline and caffeine to be 2mins, 3mins, 3.5mins,4.2mins and 5.8 mins. The
changes in the peak positions could be caused by the changes in mobile phase or temperature
changes.
Several purification protocols were adopted in purifying the human reductase enzyme
afterwards after the depletion of the purified version and unfortunately the concentration yield
was too low which affected the metabolism of caffeine assay since there were no metabolite
peaks to be observed. A rat reductase gene was purchased instead and a purification protocol is
to be developed to improve the yield.
We were able to observe some of the metabolites produced by CYP1A2 such as
theobromine, theophylline and paraxanthine.
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CHAPTER 6: FUTURE DIRECTIONS

For the future directions of these projects, further assays need to be completed to
determine the optimal assay time and kinetic parameters with CYP 1A2. Also, full standard
calibration samples need to be run so that the amounts of metabolites that are produced can be
quantified. This can be achieved by preparation of different standards of caffeine, theobromine,
theophylline and paraxanthine with different known concentration to be used in the assay.
Paraxanthine was not used in this assay because it is expensive, however this has to be
considered in standard preparation. These is dependent on the yield of the reductase enzyme
obtained after purification and dialysis.
Different commercial screens are to be used to determine the right conditions favorable
for the crystal growth of both CYP 2U1 and canine CYP 1A2 before optimization in order to
determine their molecular structures. The concentration of these proteins after purification play a
major role in crystal growth, a factor that has to be considered as well.
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CHAPTER 8. APPENDIX - A SUMMARY OF EXPRESSION AND PURIFICATION
CONDITIONS CYP 1A2 AND 2U1 AND CORRESPONDING YIELDS

Condition
3.2mM of Cymal-5 detergent
used on both the protein and
the buffers. Cobalt column
was used for affinity
chromatography.
Cobalt column was used with
the pH of the buffers adjusted to
7.4. Same concentration of
Cymal-5 detergent used.
Same conditions were used.
Increased IPTG and ALA to
0.72g

10% anapole-35 detergent
adopted for protein extraction.

1% CHAPs detergent added in
the protein with 0.5% in the
buffer solutions.

Nickel column was used for
affinity and DEAE beads for
ion- exchange
chromatography. CHAPs
detergent used.

Yield

Outcome

The protein precipitated
Some of the protein eluted without binding at the CM
with the wash buffer and column. The pH of the
proceeded to be purified
buffer used was not
further by ion exchange
adjusted. Might have been
using CM beads.
the cause for precipitation.
The same yield was
obtained as before and
CM beads used for ion
exchange purification.
Low yields obtained with
the wash buffer. Ionexchange done with CM
beads.
Low yields obtained;
protein eluted with the
wash buffer. Ion- exchange
done with CM beads.

The protein did not bind to
the CM column. The
concentration of IPTG and
ALA were adjusted.
Protein precipitation
occurred. Had to use a
different detergent.
The protein precipitated
again. CHAPs detergent
used in the next
purification.

The yield was low.
Proceeded for ion
exchange purification with
CM beads.
Protein precipitated.
The protein was saved for
crystallography and the
condition adopted for
The results were better with purification. The final yield
the protein eluting with the was not enough and 6L of
elution buffer in both
TB media were used
purification steps.
instead of 3L.
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